51
Views
0
CrossRef citations to date
0
Altmetric
Corrigendum

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum]

Page 241 | Published online: 18 Jan 2019
This article refers to:
Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study

Casas A, Montes de Oca M, Menezes AMB, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556.

Page 1552, Disclosure, the text “AM has been paid for her work as a statistician for the LASSYC study. LR is an employee of AstraZeneca. The other authors report no conflicts of interest in this work” should read “AMM has been paid by AstraZeneca and GlaxoSmithKline for her work as a statistician for the LASSYC and PLATINIO studies, respectively. LR is an employee of AstraZeneca. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.